- Clinical Development
- Therapeutic Expertise
- News & Resources
As a full service CRO, we can handle all aspects of your Phase I – IV clinical trials. We have managed over 3400 projects across all phases of clinical development. Spanning first in human through commercialization we can perform small to complex studies delivering quality services and timely results. You can outsource only as much help as you need; we provide a reliable and experienced expansion to your in-house team.
Our wide array of therapeutic expertise enables us to address the most demanding drug development challenges. In addition, over our two decade history, we have saved many studies and become known for our unique rescue study expertise. We collaborate with you to develop a better future for patients by bringing our expertise to clinical development through the commitment of our employees.
Our experience includes:
Since 1995, our team of clinical research professionals has routinely managed and delivered many successful Early Phase studies covering a wide range of pharmacokinetic and pharmacodynamic studies across the major therapeutic areas and routes of administration.
SynteractHR has experience delivering Phase II – III studies across all major therapeutic areas, from larger and more complex global studies to smaller, regionally-based trials. With our full range of services, you gain end-to-end planning to build quality into your trials from the start, to mitigate risk, gain cost and time efficiencies, and optimize performance to meet critical milestones. Our experienced clinical operations team provides strong site management and enrollment strategies while our medical monitors provide vital oversight with a strong focus on safety. Our teams support multiple software and technology platforms to deliver high quality data and robust biostatistics services, on time and without surprises. We have conducted multiple trials internationally, tapping into our network of global CRO partners as needed.
With product approval in hand, a critical phase of the drug development process begins. At SynteractHCR, we recognize post-approval studies are a valuable commercial investment, especially given payer power and regulatory requirements. We also understand the distinct nuances in the successful design and implementation of post- approval studies from that of pre-approval development. SynteractHCR’s post approval support has been in both regional and national studies and large global programs. For example, SynteractHCR is currently performing registries from 100 patients to over 140,000 on an international scale.
Our post approval support involves deploying project managers and clinical development professionals experienced in delivering services for this unique phase of your program, from consultative design and data collection through robust reporting. We focus on providing specific services designed to support products from the point of approval / marketing authorization through launch and beyond.